Zelluna

Mindre end 1K følgere

ZLNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Markedsværdi

-

Aktieomsætning

-

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

23.4

2026

Generalforsamling '26

7.5

2026

Delårsrapport Q1'26

20.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse27.3.2026, 09.01

Zelluna ASA – Mandatory notification of trade

Selskabsmeddelelse26.3.2026, 14.28

ZLNA: Zelluna to host Capital Markets Update 2026

Selskabsmeddelelse26.3.2026, 14.28

Zelluna to host Capital Markets Update 2026

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse26.3.2026, 07.56

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Selskabsmeddelelse25.3.2026, 06.00

Zelluna ASA [ZLNA]: Annual Report 2025

Selskabsmeddelelse9.3.2026, 07.00

ZLNA: Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering

Selskabsmeddelelse9.3.2026, 07.00

Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering

Selskabsmeddelelse20.2.2026, 13.30

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

Selskabsmeddelelse12.2.2026, 06.00

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission

Selskabsmeddelelse11.2.2026, 07.00

ZLNA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Selskabsmeddelelse11.2.2026, 07.00

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Selskabsmeddelelse5.2.2026, 12.30

Zelluna ASA - Grant of Share Options

Selskabsmeddelelse5.2.2026, 08.30

Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation

Selskabsmeddelelse3.2.2026, 07.00

ZLNA: Zelluna promotes Emilie Gauthy to Chief Technology Officer

Selskabsmeddelelse3.2.2026, 07.00

Zelluna promotes Emilie Gauthy to Chief Technology Officer

Selskabsmeddelelse15.1.2026, 11.22

Zelluna ASA: Approval and publication of prospectus

Selskabsmeddelelse17.12.2025, 16.26

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours

Selskabsmeddelelse16.12.2025, 11.36

ZLNA: Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Selskabsmeddelelse16.12.2025, 11.36

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Pressemeddelelse15.12.2025, 13.33

BioStock: Zelluna: killer cells tackling the solid cancer bottleneck

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.